title: Perspective of clinical research in follicular NHL: interaction between science and industry.
abstract: Despite advancements in the treatment of follicular lymphoma (FL), curative therapy remains an elusive unmet medical need. Improvements in progression-free survival result in new logistical and financial challenges to clinical investigation and drug development in this indolent disease. Surrogate endpoints that utilize imaging and sensitive markers of treatment effect may serve to address this problem. Additionally, alternative trial designs may help to bypass some of the logistical hurdles.
authors.affiliation: Genentech BioOncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA. fine.gregg@gene.com
authors.forename: Gregg
authors.initials: G
authors.lastname: Fine
authors.forename: Sandra
authors.initials: S
authors.lastname: Horning
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis*; D035843:Biomedical Research / Q000191:economics / Q000639:trends*; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D015415:Biomarkers